drugset / Trial / NCT00151801

Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients

NCT00151801

Phase 2 Unknown 200 enrolled S. Andrea Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Clinical and experimental evidences suggests an immunomodulatory effect of sex hormones in multiple sclerosis. The role of oral estroprogestins in the pathogenesis and in the clinical course of the disease is actually unknown. The aim of the study is to investigate safety and tolerability of association of estroprogestins in two different doses with interferon-beta 1a in patients with relapsing-remitting multiple sclerosis.

Timeline

Start
2002-05
Primary completion
Completion
2008-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Desogestrel Small molecule 25 ug Oral
Subject Desogestrel Small molecule 125 ug Oral
Subject Desogestrel Small molecule 150 ug Oral
Subject ethinyl estradiol Small molecule 20 ug Oral
Subject ethinyl estradiol Small molecule 40 ug Oral
Background Interferon beta-1a Protein / enzyme biologic 44 ug Subcutaneous

Indications